Apple becomes the first company to hit $1 trillion stock market valuation.

Becky Berkman

2018-08-01 11:43:00 Wed ET

Apple becomes the first company to hit $1 trillion stock market valuation. The tech titan sells about the same number of smart phones or 41 million iPhones and other mobile devices in 2018Q2 in comparison to 2017Q2. Thanks to its flagship iPhone X, Apple substantially boosts the average price per unit to $724. Due to this higher average price per unit, Apple rakes into $11.5 billion net profits in 2018Q2.

Apple's iPhones remain its most important products and account for about 60% of total revenue. Total sales grow 17% to $53.3 billion with a healthy EPS of $2.2 per share. Services sales also grow 31% to $9.6 billion, thus this trend is on track for services sales to double by 2020.

Apple sits on more than $240 billion cash stockpiles and now plans to return to its shareholders in the form of $100 billion share repurchases. In response, the stock market rewards this outperformance with a whopping 5% share price increase.

Apple's ascent beyond $1 trillion in stock market value then confirms a remarkable turnaround from the brink of bankruptcy about 2 decades ago. Meanwhile, Apple CEO Tim Cook needs to evaluate the effect of new tariffs on Chinese imports that may affect Apple Watch sales in recent consultation with the Trump administration.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma.

Rose Prince

2018-11-23 09:39:00 Friday ET

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma.

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma. After the U.S. midterm electio

+See More

Federal Reserve remains patient on future interest rate adjustments due to trade and fiscal budget negotiations.

Becky Berkman

2019-02-04 07:42:00 Monday ET

Federal Reserve remains patient on future interest rate adjustments due to trade and fiscal budget negotiations.

Federal Reserve remains patient on future interest rate adjustments due to global headwinds and impasses over American trade and fiscal budget negotiations.

+See More

Business leaders often think from a systemic perspective, share bold visions, build great teams, and learn new business models.

Becky Berkman

2020-08-05 08:33:00 Wednesday ET

Business leaders often think from a systemic perspective, share bold visions, build great teams, and learn new business models.

Business leaders often think from a systemic perspective, share bold visions, build great teams, and learn new business models. Peter Senge (2006) &nb

+See More

Macro eigenvalue volatility helps predict some recent episodes of high economic policy uncertainty.

James Campbell

2020-09-15 08:38:00 Tuesday ET

Macro eigenvalue volatility helps predict some recent episodes of high economic policy uncertainty.

Macro eigenvalue volatility helps predict some recent episodes of high economic policy uncertainty, recession risk, or rare events such as the recent rampan

+See More

Can the Chinese renminbi become the next dual global reserve currency in addition to the American dollar?

Daphne Basel

2020-08-01 07:28:00 Saturday ET

Can the Chinese renminbi become the next dual global reserve currency in addition to the American dollar?

Technological advances, geopolitical risks, and pandemic outbreaks cannot shake investor confidence in the American dollar as the global reserve currency.

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More